Written question asked by Kevin Barron (Labour), in the House of Commons. It was due for an answer on Tuesday, 12 November 1996. It was answered by Gerald Malone (Conservative) on Tuesday, 12 November 1996 on behalf of the Department of Health.
Dept of Health
- Question
- What assessment he has made of the impact of the extension of the Prodigy pilot study on (a) inward investment by non-United Kingdom-owned pharmaceutical companies, (b) research and development expenditure by the United Kingdom pharmaceutical industry, (c) export performance by the United Kingdom pharmaceutical industry and (d) the introduction in the United Kingdom of new medicines. - None.
- Answer
-
Mr. Barron: To ask the Secretary of State for Health what assessment he has made of the impact of the extension of the Prodigy pilot study on (a) inward investment by non-United Kingdom-owned pharmaceutical companies, (b) research and development expenditure by the United Kingdom pharmaceutical industry, (c) export performance by the United Kingdom pharmaceutical industry and (d) the introduction in the United Kingdom of new medicines; and if he will make a statement. [3294] Mr. Malone: None.
Secondary information
- Type
- Written question
- Reference
- 3294; 285 c155W
- Session
- 1996-97
- Subjects
- Software Drugs Industry General practitioners Prescriptions
Librarians' tools
- Timestamp
- 2024-12-25 19:57:17 +0000
- URI
- http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_241967
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_241967
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_241967